File(s) under permanent embargo
Bertilimumab (Cambridge Antibody Technology Group)
journal contribution
posted on 2023-05-26, 10:28 authored by Ding, C, Li, J, Zhang, XCambridge Antibody Technology (CAT) is developing bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.
History
Publication title
Current Opinion in Investigational DrugsVolume
5Article number
11Number
11Pagination
1213-1219ISSN
1472-4472Publication status
- Published
Repository Status
- Restricted
